Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eisai
Marketing
Leqembi launch hamstrung by physicians' 'therapeutic nihilism'
A Reuters report suggests Eisai and Biogen's launch faces a fundamental problem: Physicians still see Alzheimer’s disease as untreatable.
Nick Paul Taylor
Apr 23, 2024 9:50am
Leqembi, Takeda, Fujifilm Diosynth—Fierce Pharma Asia
Apr 19, 2024 9:20am
Eisai supports creation of Alzheimer's podcast miniseries
Apr 12, 2024 11:58am
Eisai, Carvykti, Ozempic biosimilar—Fierce Pharma Asia
Apr 5, 2024 8:25am
Eisai, Biogen's subQ Leqembi delayed amid FDA's data request
Apr 1, 2024 10:45am
Eisai, Sumitomo, Kyowa Kirin and more—Fierce Pharma Asia
Mar 8, 2024 9:42am